Intravenous Lormetazepam during Sedation Weaning in a 26-Year-Old Critically Ill Woman
Joint Authors
Luetz, Alawi
Weiss, Bjoern
Spies, Claudia D.
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-10-08
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Recent evidence revealed that sedation is related to adverse outcomes including a higher mortality.
Despite this fact, patients sometimes require deep sedation for a limited period of time to control, for example, intracranial hypertension.
In particular in these cases, weaning from sedation is often challenging due to emerging agitation, stress, and delirium.
The submitted research letter reports a rare case of severe and persisting agitation that was unresponsive to all available treatments.
Ultimately, lormetazepam which has recently become available for intravenous use in Germany resolved the problem by stress-reduction and anxiolysis without leading to measurable sedation.
American Psychological Association (APA)
Luetz, Alawi& Weiss, Bjoern& Spies, Claudia D.. 2014. Intravenous Lormetazepam during Sedation Weaning in a 26-Year-Old Critically Ill Woman. Case Reports in Critical Care،Vol. 2014, no. 2014, pp.1-4.
https://search.emarefa.net/detail/BIM-1016885
Modern Language Association (MLA)
Luetz, Alawi…[et al.]. Intravenous Lormetazepam during Sedation Weaning in a 26-Year-Old Critically Ill Woman. Case Reports in Critical Care No. 2014 (2014), pp.1-4.
https://search.emarefa.net/detail/BIM-1016885
American Medical Association (AMA)
Luetz, Alawi& Weiss, Bjoern& Spies, Claudia D.. Intravenous Lormetazepam during Sedation Weaning in a 26-Year-Old Critically Ill Woman. Case Reports in Critical Care. 2014. Vol. 2014, no. 2014, pp.1-4.
https://search.emarefa.net/detail/BIM-1016885
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1016885